losartan has been researched along with 1-(5-isoquinolinesulfonyl)-2-methylpiperazine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, BH; Chua, CC; Hamdy, RC | 2 |
| Hui, J; Jiang, W; Yang, X | 1 |
| Fan, YP; Puri, RN; Rattan, S | 1 |
| Alfarano, C; Cerbai, E; Failli, P; Franchi-Micheli, S; Mannucci, E; Mugelli, A; Raimondi, L | 1 |
| Anderson, S; Beard, DR; Komers, R; Lotspeich, DF; Oyama, TT; Tikellis, C; Xu, B | 1 |
6 other study(ies) available for losartan and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
| Article | Year |
|---|---|
Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blotting, Northern; Cell Line; Cycloheximide; Dactinomycin; Endothelium; Enzyme Inhibitors; Gene Expression Regulation; Imidazoles; Losartan; Membrane Glycoproteins; Myocardium; Protein Kinase C; Pyridines; Rats; Tetrazoles; Thrombospondins | 1997 |
Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Antihypertensive Agents; Blotting, Northern; Cattle; Culture Media, Conditioned; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Immunoblotting; Losartan; Lymphokines; Nucleic Acid Synthesis Inhibitors; Protein Kinase C; Protein Synthesis Inhibitors; Pyridines; Rats; RNA, Messenger; Transcription Factors; Transcriptional Activation; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasoconstrictor Agents | 1998 |
Angiotensin II type 1 receptor modulation of L-type calcium currents in guinea-pig ventricular cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium Channels, L-Type; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guinea Pigs; Heart Ventricles; Losartan; Membrane Potentials; Patch-Clamp Techniques; Protein Kinase C; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Ventricular Function | 2001 |
Comparison of angiotensin II (Ang II) effects in the internal anal sphincter (IAS) and lower esophageal sphincter smooth muscles.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anal Canal; Angiotensin II; Animals; Dose-Response Relationship, Drug; Drug Combinations; Esophagus; Female; Flavonoids; Genistein; Imidazoles; Losartan; Male; Muscle Contraction; Muscle, Smooth; Nicardipine; Opossums; Pyridines; Rabbits; Species Specificity; Tyrphostins | 2002 |
Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Biphenyl Compounds; Diabetes Mellitus, Experimental; In Vitro Techniques; Irbesartan; Losartan; Male; Rats; Rats, Wistar; rho-Associated Kinases; Tetrazoles; Up-Regulation; Vasoconstriction | 2009 |
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Gene Expression; Kidney; Losartan; Male; Membrane Proteins; Nephrectomy; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vascular Endothelial Growth Factor A | 2011 |